Benzinga | Oct 15, 2020 07:11AM EDT

Leap Therapeutics To Present Esophagogastric Cancer Data At SITC 2020 Annual Meeting Nov. 9

CAMBRIDGE, Mass., Oct. 15, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting esophagogastric cancer data for its DKN-01 monoclonal antibody at the Society of Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, being held November 9-14, 2020 virtually.

Leap Presentation Details:

Title: Tumoral DKK1 expression correlates with better clinical outcomes in patients with advanced esophagogastric cancer (EGC) treated with DKN-01

Presenter: Samuel J. Klempner, MD, Massachusetts General Hospital Cancer Center

Abstract ID: 262

Date: Available on demand on Monday, November 9, 2020 at 8:00 a.m. ET

About DKN-01